ASTX029

DRUG3 trials

Sponsors

Taiho Oncology, Inc., Astex Pharmaceuticals, Inc., M.D. Anderson Cancer Center

Conditions

Healthy VolunteersMyelodysplastic NeoplasmMyeloproliferative NeoplasmPathway Mutant Myelodysplastic SyndromesSolid Tumor, Adult

Phase 1

Study of ASTX029 in Subjects With Advanced Solid Tumors

CompletedNCT03520075

Taiho Oncology, Inc.Solid Tumor, Adult

Start: 2018-05-07End: 2025-03-03Updated: 2025-07-03

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

CompletedNCT04466514

Astex Pharmaceuticals, Inc.Healthy Volunteers

Start: 2020-07-23End: 2020-10-06Updated: 2024-08-02

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

WithdrawnNCT06284460

M.D. Anderson Cancer CenterMyelodysplastic Neoplasm, Myeloproliferative Neoplasm, Pathway Mutant Myelodysplastic Syndromes

Start: 2025-01-31End: 2027-12-01Updated: 2026-02-13

Related Papers

ERK1/2 Inhibition Mediates Bax Dependent Proteolysis of OPA1 and Induces Mitochondrial Cristae Remodeling to Overcome Resistance to Venetoclax

Blood2024-11-051 citations

Abstract B164: ASTX029 is a dual mechanism ERK1/2 inhibitor with activity in models of MAPK-inhibitor resistance

Molecular Cancer Therapeutics2023-12-01

Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

Blood2022-11-152 citations

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

Blood2022-11-151 citations

Abstract 3365: Transcriptomics-based stratification of response to MAPK inhibition <i>in vitro</i> better predicts sensitivity to single agent and combination treatment than MAPK genomic alteration status alone

Cancer Research2022-06-15

A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.

Journal of Clinical Oncology2022-06-011 citations

Abstract P112: Treatment with the dual-mechanism ERK inhibitor, ASTX029, alters myeloid cell differentiation

Molecular Cancer Therapeutics2021-12-01

ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics

Blood2021-11-054 citations

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK

Molecular Cancer Therapeutics2021-07-3032 citations

Abstract 1661: Immune modulation by the dual-mechanism ERK inhibitor, ASTX029, in MAPK-activated tumor models

Cancer Research2021-07-01

Abstract CT108: A first-in-human, Phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors

Cancer Research2021-07-01

Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models

Blood2020-11-041 citations